I am going to meet my supervisor For synopsis topics and Theseare my topics
It looks like your message got cut off - the topics didn't come through! Could you please share the synopsis topics you'd like to discuss?
Comparison of Intravenous versus Topical Lignocaine on Perfusion Index, Rate Pressure Product, and Hemodynamic Stress Response during Laryngoscopy and Intubation.*
Asking for Preferences
Reading File
Searching PubMed
lignocaine intravenous topical laryngoscopy intubation hemodynamic stress response
Searching the Web
IV vs topical lignocaine laryngoscopy intubation perfusion index rate pressure product hemodynamic study
Searching PubMed
lignocaine lidocaine laryngoscopy intubation hemodynamic
Searching PubMed
perfusion index laryngoscopy intubation stress response
Finding Sources
Reading Web Page
IV vs topical lignocaine laryngoscopy intubation perfusion index rate pressure product hemodynamic
Reading Article
Reading Article
Reading Article
Finding Sources
Finding Sources
Searching PubMed
rate pressure product laryngoscopy intubation anesthesia
Reading Article
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
I now have sufficient material from textbooks, PubMed RCTs, and literature to compile a thorough synopsis brief. Here is the complete write-up:
Synopsis Brief: IV vs Topical Lignocaine - Perfusion Index, RPP & Hemodynamic Stress Response During Laryngoscopy and Intubation
1. Background and Rationale
Laryngoscopy and endotracheal intubation (LETI) are among the most potent nociceptive stimuli encountered in routine anesthetic practice. They trigger a sympathoadrenal surge mediated by stimulation of the supraglottic structures (epiglottis, aryepiglottic folds) and the subglottic trachea, leading to a transient but clinically significant rise in heart rate (HR), systolic blood pressure (SBP), and circulating catecholamines. This pressor response typically peaks within 30-90 seconds of intubation and lasts 5-10 minutes.
In healthy patients this response is usually self-limiting, but in those with ischemic heart disease, hypertension, cerebrovascular disease, or raised intracranial pressure, the surge can precipitate:
- Myocardial ischemia or infarction
- Left ventricular failure
- Dysrhythmias
- Intracranial hemorrhage or herniation
Attenuating this response is therefore a fundamental goal of safe anesthetic induction.
2. Why Lignocaine?
Lignocaine (lidocaine) is the most widely studied agent for blunting the intubation stress response. It works by:
- Sodium channel blockade - suppresses afferent neural firing from laryngotracheal mucosa
- Membrane stabilization - decreases excitability of cardiovascular effectors
- Suppression of the cough reflex - reduces the reflex arc that amplifies the sympathetic surge
Two principal delivery routes are used clinically:
| Route | Dose | Timing | Mechanism |
|---|---|---|---|
| Intravenous (IV) | 1.5 mg/kg | 90-120 sec before laryngoscopy | Systemic Na-channel blockade; direct cardiac membrane effect |
| Topical (spray/nebulized/transtracheal) | 1.5-2 mg/kg | After induction, before intubation | Local mucosal analgesia; blunts afferent arc at source |
3. The Three Key Outcome Measures - Conceptual Basis
A. Hemodynamic Stress Response (HR, SBP, DBP, MAP)
The classical outcome. Measured at baseline, post-induction, and at 1, 3, 5 min post-intubation. Rise in HR and MAP >20% from baseline is considered a significant pressor response.
B. Rate Pressure Product (RPP)
RPP = Heart Rate × Systolic Blood Pressure
RPP is a non-invasive surrogate of myocardial oxygen demand. As confirmed in Pfenninger and Fowler's Procedures for Primary Care (p. 595):
"One method of quantifying the overall myocardial oxygen demand is to multiply the SBP by the heart rate; the product obtained is the double product, also known as the rate-pressure product (RPP). At any given moment the RPP is therefore an estimate of total myocardial oxygen demand."
- Normal resting RPP: ~7,000-10,000 mmHg·beats/min
- An RPP >12,000 is associated with subendocardial ischemia
- RPP integrates both heart rate and pressure responses, making it more sensitive than either variable alone
The novelty and clinical importance of including RPP in your study: it translates the hemodynamic data directly into a measure of cardiac work - directly relevant to patients at risk of perioperative myocardial events.
C. Perfusion Index (PI)
PI is the ratio of pulsatile to non-pulsatile infrared light absorption at the peripheral pulse oximeter probe, expressed as a percentage.
- High PI = good peripheral perfusion, low sympathetic tone
- Low PI = peripheral vasoconstriction, high sympathetic tone
During laryngoscopy and intubation, the sympathoadrenal surge causes peripheral vasoconstriction, which drops PI acutely. A 2023 observational study (PMID 37088851 - Shah et al.) directly validated this:
"Baseline PI was 4.14. PI plummeted at laryngoscopy (3.24), remained low at 1 min (3.68), 3 min (4.69) thereafter... PI displays a negative correlation with hemodynamic variables."
PI is non-invasive, real-time, and continuous - derived from a standard pulse oximeter. This makes it a practical and novel stress biomarker suitable for resource-limited settings. Its inclusion distinguishes your study from conventional hemodynamic-only designs and is a strong point to defend with your supervisor.
4. Literature Gap - Justifying Your Study
Most existing RCTs compare lignocaine against other drugs (esmolol, dexmedetomidine, fentanyl, magnesium, clonidine). Studies directly comparing IV vs Topical lignocaine using all three outcomes simultaneously (PI + RPP + hemodynamics) are sparse:
| Study | Comparison | Key Finding |
|---|---|---|
| Pramanik et al., 2025 (PMID 40413425) | Transtracheal vs IV lignocaine 2% (1.5 mg/kg) | Transtracheal superior - less post-intubation surge in MAP and HR at 3 min |
| Huan et al., 2024 (PMID 39270370) | Topical laryngeal spray vs saline | Spray reduced MAP, HR, catecholamines, and blood glucose significantly |
| Varshney et al., 2019 (PMID 31897315) | Lignocaine spray vs NTG spray | Both attenuated RPP; NTG more effective for blood pressure component |
| Abedzadeh et al., 2024 (PMID 37929508) | Lignocaine gargling + additives | Gargling reduces sore throat; hemodynamic data limited |
No published RCT has simultaneously evaluated PI, RPP, and conventional hemodynamics as primary/secondary outcomes when comparing IV versus topical lignocaine head-to-head in a general surgical population. This is your gap.
5. Proposed Study Design
Study type: Prospective, randomized, double-blind controlled trial
Population:
- Adults 18-60 years, ASA grade I-II
- Scheduled for elective surgery requiring general anesthesia with orotracheal intubation
- Exclude: known hypertension, IHD, cerebrovascular disease, obesity (BMI >35), anticipated difficult airway, patients on antihypertensives or beta-blockers
Groups (n = ~40-50 per group, calculate with 80% power, alpha 0.05):
- Group IV: Lignocaine 1.5 mg/kg IV at 90 sec before laryngoscopy + topical saline spray
- Group T: Topical lignocaine spray 2 mg/kg to oropharynx/larynx post-induction + IV saline
Primary Outcomes:
- Perfusion Index at baseline, post-induction, at laryngoscopy, 1 min, 3 min, 5 min post-intubation
- Rate Pressure Product at the same time points
Secondary Outcomes:
- Heart rate, SBP, DBP, MAP at all time points
- Incidence of significant pressor response (HR/MAP >20% rise)
- Adverse effects: hypotension, arrhythmias, coughing, PONV
Standardized induction protocol (to control confounders):
- Midazolam 0.02 mg/kg + Fentanyl 2 mcg/kg + Propofol 1.5-2 mg/kg + Vecuronium 0.1 mg/kg
- One experienced anesthesiologist performs all intubations
- Fixed laryngoscopy duration (cut-off at 30 sec for failed attempts)
6. Points to Defend With Your Supervisor
Q: Why compare IV vs Topical lignocaine specifically - not lignocaine vs another drug?
A: Lignocaine is the most cost-effective, widely available, and safe option. The route of administration determines onset, duration, and mechanism of action. The IV route achieves systemic plasma levels quickly; topical acts at the mucosa and blunts the afferent arc at source. The 2025 RCT by Pramanik et al. (transtracheal vs IV) showed superiority of local delivery - but transtracheal injection carries risks (coughing, subglottic edema). Topical spray is simpler and safer. The question of IV vs topical spray in a head-to-head comparison with PI as a novel endpoint remains unanswered.
Q: Why include Perfusion Index?
A: PI is a validated, continuous, non-invasive index of peripheral sympathetic tone. Its fall at laryngoscopy is well-documented. It provides real-time feedback on the stress response without requiring arterial lines or plasma catecholamines. It correlates negatively with hemodynamic variables and may be more sensitive to early sympathetic activation.
Q: Why Rate Pressure Product?
A: RPP translates hemodynamics into a measure of myocardial oxygen demand, which is the clinically relevant endpoint - not just the number on the blood pressure monitor. RPP >12,000 marks the ischemic threshold and makes your study directly relevant to perioperative cardiac safety.
Q: Is 1.5 mg/kg the right dose for both routes?
A: Yes - this is the dose validated in multiple RCTs for both IV (standard) and transtracheal/topical (Pramanik 2025 used this for both arms). It keeps the comparison equitable and avoids the confounder of dose disparity.
7. Key References to Cite
-
Pramanik M et al. Comparison between transtracheal and intravenous 2% lignocaine in attenuating hemodynamic stress response following direct laryngoscopy and endotracheal intubation: a randomized controlled trial. BMC Anesthesiol. 2025. [PMID 40413425]
-
Huan Liu et al. Topical larynx lidocaine spraying reduces cardiovascular stress response caused by suspension laryngoscopic surgery. Braz J Otorhinolaryngol. 2024. [PMID 39270370]
-
Varshney RK et al. Comparison of nitroglycerin versus lignocaine spray to attenuate haemodynamic changes during direct laryngoscopy and endotracheal intubation. Sultan Qaboos Univ Med J. 2019. [PMID 31897315]
-
Shah SB et al. Assessment of stress response due to videolaryngoscopic endotracheal intubation using perfusion index. J Clin Monit Comput. 2023. [PMID 37088851]
-
Pfenninger and Fowler's Procedures for Primary Care - RPP as measure of myocardial oxygen demand (p. 595)
-
Barash, Cullen, Stoelting's Clinical Anesthesia, 9e - Hemodynamic responses to laryngoscopy and intubation; opioid/adjunct use
8. Likely Supervisor Questions and Suggested Answers
| Question | Answer |
|---|---|
| Sample size justification? | Based on a 20% difference in PI change from baseline; SD from pilot data or published studies; 80% power, alpha 0.05 - typically requires 40-50 per group |
| How will you blind the patient to route? | Patient receives IV injection + oropharyngeal spray in both groups - one is active, the other is saline. Both administered at the same time points. |
| What is your primary endpoint? | Perfusion Index and RPP - measured continuously; the novel and clinically meaningful endpoints |
| Ethical concern - toxicity? | 1.5 mg/kg IV lignocaine is well within safe plasma levels (<5 mcg/mL); topical 2 mg/kg is also within safe limits for mucosal application |
| How to ensure standardized intubation time? | Single experienced laryngoscopist; stopwatch-timed; attempts >30 sec excluded from analysis |
This topic is well-constructed, clinically relevant, and has a demonstrable gap in the existing literature. The inclusion of Perfusion Index and RPP as novel outcome measures is your strongest differentiator. Good luck with your synopsis meeting!
: *Comparison of effect of induction of general anesthesia with propofol vs ketamine +midazolam on perfusion index in cardiac patients undergoing non cardiac surgery*we will remove similaritiea of this topic with mine
Searching PubMed
propofol ketamine midazolam induction cardiac patients non-cardiac surgery perfusion index
Searching the Web
propofol vs ketamine midazolam induction perfusion index cardiac non-cardiac surgery hemodynamic study
Here is the complete side-by-side analysis and a strategy to eliminate all meaningful overlaps:
Differentiating Your Two Topics
Side-by-Side Comparison
| Element | Colleague's Topic | Your Topic |
|---|---|---|
| Intervention | Induction agent: Propofol vs Ketamine+Midazolam | Lignocaine route: IV vs Topical |
| Phase of anesthesia | Induction phase | Pre-laryngoscopy / intubation phase |
| Patient population | Cardiac patients undergoing non-cardiac surgery | General elective surgical patients (ASA I-II) |
| Primary drug class | Induction hypnotics / dissociative agents | Local anesthetic (adjunct) |
| Shared outcome | Perfusion Index (PI) | Perfusion Index (PI) |
| Their other outcomes | Hemodynamics during induction | RPP + hemodynamics during laryngoscopy |
| Research question | Which induction agent causes less hemodynamic depression/stimulation? | Which route of lignocaine better blunts the intubation stress response? |
| Timing of PI measurement | Peri-induction (before and after induction drugs) | Peri-intubation (after induction, around laryngoscopy) |
Where the Overlap Lies
The only real overlap between the two topics is the use of Perfusion Index as an outcome measure. Everything else is different:
- Different drug class
- Different phase of anesthesia
- Different patient population
- Different clinical question
- Different stress stimulus (induction vs laryngoscopy)
How to Eliminate Even the PI Overlap
There are two clean strategies:
Option 1 - Keep PI but reframe it clearly (Recommended)
Do NOT remove PI from your study. Instead, reframe it explicitly in your title and objectives to show it measures a fundamentally different phenomenon:
- Colleague uses PI to assess hemodynamic depression during induction
- You use PI to assess sympathetic activation / peripheral vasoconstriction during laryngoscopy
PI drops during induction (vasodilation from propofol) and also drops during laryngoscopy (sympathetic vasoconstriction) - these are physiologically opposite mechanisms, making the two studies entirely distinct even with the same tool.
Revised title suggestion:
"Comparison of Intravenous versus Topical Lignocaine on Perfusion Index as a Marker of Sympathoadrenal Stress Response, Rate Pressure Product, and Hemodynamics during Laryngoscopy and Endotracheal Intubation"
This framing makes PI a stress marker in your study versus a perfusion/depression marker in the colleague's study.
Option 2 - Replace PI with a different novel outcome
If your supervisor insists on removing PI entirely to avoid any visual similarity, replace it with one of these:
| Replacement Outcome | Rationale |
|---|---|
| Pleth Variability Index (PVI) | Derived from same pulse oximeter; reflects fluid responsiveness; not used in colleague's study |
| SpO₂ waveform amplitude | Raw plethysmographic signal amplitude; reflects vasoconstriction; different metric entirely |
| Double Product (same as RPP) | Keep RPP as your novel outcome - colleague does not use this |
| Bispectral Index (BIS) | Depth of anesthesia; relevant to intubation stress; totally absent from colleague's topic |
The simplest, cleanest option: Just keep RPP and hemodynamics as your primary outcomes and remove PI. RPP is already a strong differentiator and requires no extra monitoring equipment.
Recommended Final Title (with PI removed if needed)
"Comparison of Intravenous versus Topical Lignocaine on Rate Pressure Product and Hemodynamic Stress Response during Direct Laryngoscopy and Endotracheal Intubation: A Randomized Controlled Trial"
- No overlap with the colleague's topic
- RPP remains your novel, distinguishing outcome
- Hemodynamics (HR, SBP, DBP, MAP) remain standard outcomes
- The entire study is mechanistically and clinically distinct
Summary of What to Tell Your Supervisor
"The only shared element between the two topics is the use of Perfusion Index as a monitoring tool. The populations, drug classes, phases of anesthesia, clinical questions, and all other outcomes are entirely different. However, to avoid any appearance of similarity, I propose either reframing PI as a stress marker (vs the colleague's use as a perfusion marker) or replacing it with Rate Pressure Product alone as my primary novel outcome, which no existing study has combined with IV vs topical lignocaine in a direct comparison."
This argument is scientifically sound and should satisfy your supervisor. The two topics can comfortably coexist in the same department.
This is a shared conversation. Sign in to Orris to start your own chat.